VALENCIA, Spain, Sept. 25, 2024
VALENCIA, Spain, Sept. 25, 2024 /PRNewswire/ -- ARTHEx Biotech S.L., a clinical-stage biotechnology company focused on developing innovative medicines through the modulation of gene expression, announced today its participation in the 8th Annual Chardan Genetic Medicines Conference, being held September 30-October 1, 2024, in New York, NY.
Advertisement
Frédéric Legros, Executive Chairman and CEO, will participate in one-on-one meetings with investors during the conference.
About ARTHEx BiotechARTHEx Biotech is a clinical-stage biotechnology company focused on developing innovative medicines through the modulation of gene expression. The Company's lead investigational compound, ATX-01, is being evaluated for the treatment of myotonic dystrophy type 1 (DM1), a rare neuromuscular disorder, in the Phase I-IIa ArthemiR™ trial. ARTHEx is also advancing its in-house discovery engine to identify and develop microRNA modulators for other disorders with high unmet medical needs, including genetically-driven diseases like DM1. The Company headquarters are in Valencia, Spain.
Advertisement
For more information, please visit www.arthexbiotech.com and engage with us on LinkedIn.
Company Contact.
Investor and Media Contact
Frédéric Legros
Amy Conrad
Executive Chairman and CEO
Juniper Point
[email protected]
[email protected]
+33679495790
+1 858-366-3243
View original content to download multimedia:https://www.prnewswire.com/news-releases/arthex-biotech-announces-participation-in-8th-annual-chardan-genetic-medicines-conference-302259080.html
SOURCE ARTHEx Biotech
